Cargando…
RBBP4 Enhances Platinum Chemo Resistance in Lung Adenocarcinoma
BACKGROUND: The majority of lung cancers are adenocarcinomas, with the proportion being 40%. The patients are mostly diagnosed in the middle and late stages with metastasis and easy recurrence, which poses great challenge to the treatment and prognosis. Platinum-based chemotherapy is a primary treat...
Autores principales: | Wang, Nianwu, Wang, Wei, Mao, Wenli, Kuerbantayi, Nazuke, Jia, Nuan, Chen, Yan, Zhou, Fang, Yin, Li, Wang, Yukun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811416/ https://www.ncbi.nlm.nih.gov/pubmed/33506032 http://dx.doi.org/10.1155/2021/6905985 |
Ejemplares similares
-
Comprehensive Analysis of the Transcriptome-wide m6A Methylome in Lung Adenocarcinoma by MeRIP Sequencing
por: Mao, Wenli, et al.
Publicado: (2022) -
Corrigendum: Comprehensive analysis of the transcriptome-wide m6A methylome in lung adenocarcinoma by MeRIP sequencing
por: Mao, Wenli, et al.
Publicado: (2022) -
The mechanism of radiotherapy for lung adenocarcinoma in promoting protein SIRT6-mediated deacetylation of RBBP8 to enhance the sensitivity of targeted therapy
por: Wang, Jiying, et al.
Publicado: (2022) -
Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
por: Li, Xin, et al.
Publicado: (2021) -
Rbbp4 Suppresses Premature Differentiation of Embryonic Stem Cells
por: Huang, Yikai, et al.
Publicado: (2021)